![No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12902-018-0291-x/MediaObjects/12902_2018_291_Fig1_HTML.png)
No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course | SpringerLink
Crossâ•'sectional area index of left ventricular myocardium as a risk factor influencing early and late postoperative survi
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-AFig-FIG01.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-002-05.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-01.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-05.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-003-01.jpg)
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC
![Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6513643/bin/nCD010747-CMP-004-02.jpg)